SHS is investing funds from its fourth fund generation to finance EIT's international growth and development of its innovative products.
3D printing, which is also known as additive manufacturing, is used to manufacture cellular and porous implants of biocompatible titanium. These implants mimic the structure and stiffness of natural bone material more accurately than implants manufactured using traditional methods
This in turn promotes bone ingrowth following fusion operations to achieve better clinical results and reduce complication rates. In addition to this, the implants can be fitted on a patient-specific basis, which serves to increase the contact surface and reduce future risks.
"Our EIT Cellular Titanium implants provide the answer to current challenges in implant design and choice of materials as well the extreme cost pressure in medical technology. The additive manufacturing technology allows us to tackle existing problems with new solutions. Thus we can improve the benefits for patients without increasing costs, which is a clear competitive advantage", explains Guntmar Eisen, founder and CEO of EIT.
"This ensures a high level of patient satisfaction and excellent clinical results. We are looking forward to pushing ahead with our international growth, especially in the United States, and our product development with our new partner SHS."
"EIT's 3D-printed spine implants have already proven their superior functionality many times in practical applications, thus promoting EIT's growth", adds Dr. Bernhard Schirmers, Managing Partner at SHS Gesellschaft für Beteiligungsmanagement.
"EIT Emerging Implant Technologies' management team is experienced and successful in the field of spine surgery. As a medical technology investor, we look forward to supporting them on their path to increased growth."
With a total volume of 125 million euro, the fourth SHS fund is focusing on expansion financing, changes in shareholder structures and successor situations. The Tübingen based investor is planning further acquisitions and investments in the fast-growing medical technology and life-science industries in Germany, Austria and Switzerland in the months ahead.
EIT is the first medical device manufacturer in the orthopedic field to exclusively focus on implants that are designed and produced with additive manufacturing methods.
EIT pushes the boundaries of traditional implant manufacturing to obtain versatile, anatomically designed porous implants with increased functionality and maximal bone ingrowth capabilities for all spinal segments.
The EIT implants made of EIT Cellular Titanium® address the shortcomings of the current designs and materials, thereby ensuring optimal clinical outcomes and maximum patient satisfaction.
EIT provides a complete spinal fusion cage portfolio. Patient specific implants to help in the treatment of complex spinal disorders as well as other interesting implant concepts are in development.
EIT consists of a team of skilled and dedicated professionals with a diverse background in management, research and development and quality assurance.
The team has a proven track record setting up and managing innovative spinal implant companies, and has developed an extensive network of contacts over many years including internationally renowned surgeons and opinion leaders in the field of spine surgery.
